Threat actors are abusing Pastebin comments to distribute a new ClickFix-style attack that tricks cryptocurrency users into ...

Net profit of Navin Fluorine International rose 121.77% to Rs 185.40 crore in the quarter ended December 2025 as against Rs 83.60 crore during the previous quarter ended December 2024. Sales rose ...

Navin Fluorine Q3 Results: Navin Fluorine International announced its results for the quarter ending December 2025 (Q3FY26) on February 2. The company posted a strong set of financial numbers, posting ...

From the moment the first photographs surfaced online, the wedding of Sahil Reddy in Chennai became more than just a family celebration. Images of former Andhra Pradesh Chief Minister Y.S. Jagan Mohan ...

Abstract: Generative artificial intelligence has become the focus of the intelligent education field, especially in the generation of personalized learning resources. Current learning resource ...

Navin Fluorine International has allotted 6,000 equity shares under ESOS on 05 February 2026. Considering this allotment, the paid-up share capital of the Company has increased to Rs 10,24,89,088/- ...

“If you’re carrying 15-20 extra pounds,” it says, “medications like Wegovy can help jumpstart your progress.” ...

Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

Beginning in 2026, the ACC's Distinguished Award for International Service will be named in honor of Navin C. Nanda, MD, FACC, thanks to the support of the American Association of Cardiologists of ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...

COLUMBIA — It took years for South Carolina legislators to broker a compromise to reform how the General Assembly picks state judges. Now, many of the same lawmakers who helped strike the deal last ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...